Bakakos Petros, Chatziapostolou Panagiotis, Katerelos Panos, Efstathopoulos Petros, Korkontzelou Aliki, Katsaounou Paraskevi
1st University Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens, "Sotiria" Chest Diseases Hospital, 11527 Athens, Greece.
Pulmonary Clinic, Euromedica General Clinic of Thessaloniki, 54645 Thessaloniki, Greece.
J Pers Med. 2022 Jan 22;12(2):146. doi: 10.3390/jpm12020146.
The fixed combination of extrafine beclometasone dipropionate 100 μg/formoterol 6 μg (extrafine BDP/F) delivered by NEXThaler has proved to be effective in patients with moderate-to-severe asthma in terms of lung function, symptoms and asthma control. The aim of this study was to investigate the usability/satisfaction of NEXThaler and adherence to treatment in asthma patients not well controlled by low-dose inhaled corticosteroids (ICS).
This was a 6-month prospective, multicenter, open-label, observational study in 661 patients with asthma not well controlled by low-dose ICS according to the physician's clinical assessment, which have received regular treatment with extrafine BDP/F NEXThaler. Feeling of Satisfaction with Inhaler (FSI), treatment adherence with self-reported Morisky scale, asthma control, lung function and QoL were recorded at baseline, 3 and 6 months after treatment with extrafine BDP/F.
The percentage of patients at least "fairly" satisfied with NEXThaler usability (FSI-10 score 40 to 50) was 96.3%. The mean FSI-10 total score was 46.8 ± 4.4 on Visit 2 and increased to 48.1 ± 3.3 on Visit 3 ( < 0.001). Approximately 67% of the patients reported "high adherence" on Visit 2, and 70% of them reported "high adherence" on Visit 3. The percentage of patients with ACQ-6-uncontrolled asthma decreased from 79.1% on Visit 1 to 22.3% on Visit 2 and further decreased to 6.7% on Visit 3. Significant improvements were also observed in the total AQLQ score, predicted FEV1% and reduction in rescue medication use.
The NEXThaler device, delivering a combination of BDP/F, achieves satisfaction and high adherence in patients with asthma not well controlled with low-dose ICS. Asthma control, QoL, lung function and rescue medication use were improved in a Greek real-world setting.
通过NEXThaler装置递送的丙酸倍氯米松超细粉100μg/福莫特罗6μg(超细BDP/F)固定复方制剂,在中重度哮喘患者的肺功能、症状及哮喘控制方面已被证明是有效的。本研究的目的是调查NEXThaler装置在未被低剂量吸入性糖皮质激素(ICS)良好控制的哮喘患者中的易用性/满意度及治疗依从性。
这是一项为期6个月的前瞻性、多中心、开放标签的观察性研究,纳入了661例根据医生临床评估未被低剂量ICS良好控制的哮喘患者,这些患者接受了超细BDP/F NEXThaler的常规治疗。在使用超细BDP/F治疗的基线、治疗后3个月和6个月时,记录吸入器满意度(FSI)、采用自我报告的Morisky量表评估的治疗依从性、哮喘控制情况、肺功能及生活质量。
至少对NEXThaler装置易用性“相当”满意(FSI-10评分40至50)的患者百分比为96.3%。第2次访视时FSI-10总分平均为46.8±4.